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Abstract: Long-term or home mechanical noninvasive ventilation (Home-NIV) has become 
a well-established form of therapy over the last few decades for chronic hypercapnic COPD 
patients in European countries. However, meta-analyses and clinical guidelines do not 
recommend Home-NIV for COPD patients on a routine basis. In particular, there is ongoing 
debate about Home-NIV in chronic hypercapnic COPD regarding the overall effects, the most 
favorable treatment strategy, the selection of eligible patients, and the time point at which it is 
prescribed. The current review focuses on specific aspects of patient selection and discusses 
the various scientific as well as clinical-guided perspectives on Home-NIV in patients suffer-
ing from chronic hypercapnic COPD. In addition, special attention will be given to the topic 
of ventilator settings and interfaces.
Keywords: exacerbation, pulmonary emphysema, hypercapnia, mechanical ventilation, respi-
ratory insufficiency
Introduction
Patients with end-stage COPD can present with hypoxemic and hypercapnic 
respiratory failure.1 Long-term oxygen therapy (LTOT) is a well-established, 
frequently prescribed treatment for hypoxemic respiratory failure that has been 
reported to improve long-term survival in patients suffering from COPD.1 Although 
long-term or home mechanical noninvasive ventilation (Home-NIV) is a widely 
accepted therapeutic option for restrictive thoracic and neuromuscular patients once 
hypercapnic respiratory failure occurs,1 this is not the case for patients with chronic 
hypercapnic COPD.2 A systemic review and data meta-analysis from 2014 concluded 
that there was not enough evidence at the time to support the routine use of Home-
NIV in patients with stable hypercapnic COPD.3 Remarkably, this is in clear contrast 
to clinical practice, where Home-NIV for chronic hypercapnic COPD has been a 
well-established treatment in many European countries during at least the last two 
decades.2,4 Furthermore, this topic has received a high amount of scientific attention, 
as demonstrated by the number of recent studies related to COPD patients and long-
term NIV following acute hypercapnic respiratory failure5,6 and chronic hypercapnic 
respiratory failure.7,8
Patients with chronic hypercapnic respiratory failure (type II) are the subgroup 
of COPD patients most likely to benefit from Home-NIV. Patients presenting with 
hypoventilation are thought to suffer from an imbalance between increased inspira-
tory muscle load and reduced inspiratory muscle capacity.1 One major limitation for 
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alveolar ventilation in advanced COPD with emphysema is 
hyperinflation-induced diaphragm shortening, which is asso-
ciated with ineffective muscle function.1 The physiological 
background and types of respiratory failure associated with 
COPD are described in more detail elsewhere.1
Patient selection and timing 
of Home-NIv
A recently published online survey of physicians involved 
in the provision of Home-NIV revealed that COPD patients 
mainly benefit from NIV in terms of a subsequent reduction 
in hospital admissions, an improvement in quality of life, 
and relief of dyspnea.2 Furthermore, both recurrent exacerba-
tions (.3) requiring NIV and failed weaning from inpatient 
NIV therapy were each found to constitute the most important 
reasons for implementing Home-NIV. Despite this, there is 
a large variability in the rate of NIV prescription for COPD 
patients among different countries.2 This variability is in 
line with that reported by the Eurovent Study (2001), which 
included 27,118 patients from 483 centers across Europe.4 
Nevertheless, there is now increasing scientific evidence 
(see in the following paragraphs) to support a number of 
indications for Home-NIV in patients suffering from chronic 
hypercapnic COPD (Table 1).
The indication for Home-NIV in the subgroup of COPD 
patients with stable chronic hypercapnic COPD has been 
a controversial topic over the last two decades.1 In three 
long-term studies published between 2000 and 2009, no 
clear benefits of NIV therapy were shown for COPD patients 
when compared with the effects of LTOT/standard therapy 
alone.1,11–13 Casanova et al (N=44) and Clini et al (N=86) 
also reported that COPD patients with moderate chronic 
hypercapnia did not gain any survival benefits from the 
introduction of Home-NIV.11,12 In a study by McEvoy et al 
(N=144), survival was found to be slightly improved by 
Home-NIV in comparison to standard therapy.13 However, 
this benefit was associated with reduced health-related 
quality of life (HRQL).13 All three studies investigated the 
effects of Home-NIV in a subgroup of COPD patients with 
a mean hypercapnia below 55 mmHg (7.33 kPa).11–13 By 
contrast, a more recent multicenter German study reported 
a substantial survival benefit for chronic hypercapnic COPD 
patients using Home-NIV in comparison to those undergo-
ing standard therapy (including LTOT alone).7 This trial 
included patients with higher mean arterial pressure of 
carbon dioxide (PaCO
2
) levels of 59 mmHg (7.8 kPa) in the 
NIV group and 58 mmHg (7.7 kPa) in the control group.7 
Furthermore, it was shown that when a multidisciplinary 
rehabilitation program for COPD patients with (moderate) 
chronic hypercapnic respiratory failure was supplemented 
with nocturnal NIV, there was an improvement in outcome 
in terms of exercise tolerance, HRQL, and lung function, in 
comparison to rehabilitation alone.8,14
This discrepancy in outcome might be explained by the 
following factors. First, it appears that severe hypercap-
nic patients benefit more from Home-NIV.1,3 Second, the 
provision of optimal standard care treatment (eg, a well-
organized rehabilitation program) enhances the positive out-
comes that are usually associated with nocturnal Home-NIV. 
Finally, the studies that showed positive outcomes used 
different approaches to ventilation, including those related to 
the settings and targets for reducing PaCO
2
 (see next section 
for more detail).
COPD patients who suffer from an acute exacerba-
tion and hence require immediate mechanical ventilation 
generally have a poor prognosis.15 The readmission rate for 
COPD patients after an exacerbation with acute hypercapnic 
respiratory failure and the need for acute NIV therapy is 
reportedly around 35% after the first month and 70% after 
4 months.16 In line with this limited prognosis, Titlestad 
et al reported that the 1-year survival rate in this subgroup 
of COPD patients is around 50%.17
Table 1 Recommendations for Home-NIV in chronic hypercapnic respiratory failure and COPD based on scientific as well as clinical-
guided perspectives
Chronic hypercapnic COPD
Hypercapnia* Daytime PaCO2 $50 mmHg ($6.67 kPa) or
Nocturnal PaCO2 $55 mmHg ($7.33 kPa) or
Daytime PaCO2 46–50 mmHg (6.13–6.67 kPa) and an increase in nocturnal PtcCO2 of 10 mmHg (1.33 kPa)
Following acute exacerbation with need for mechanical ventilation
Persistent hypercapnia* 14–28 days following acute NIv due to 
respiratory acidosis
Daytime PaCO2 .53 mmHg ($7.07 kPa)
weaning failure** Following mechanical ventilation 
(NIv or invasive ventilation) in hospital
and persistent ventilatory failure without NIv
Notes: *Represents scientific perspectives and **represents clinical-guided perspectives. Data from Windisch et al,1 Crimi et al,2 Struik et al,3 Murphy et al,6 Köhnlein et al,7 
windisch et al,9 and Schönhofer et al.10
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In response to these poor outcome data, studies were 
initiated to investigate whether survival could be improved 
with the continuation of Home-NIV after an exacerbation.5,6,15 
Struik et al investigated the effect of Home-NIV versus 
standard medical treatment in COPD patients with pro-
longed hypercapnia after acute respiratory failure requiring 
acute NIV therapy.5 A total of 201 patients with a PaCO
2
 
level of .45 mmHg (6.0 kPa) after 48 hours of termination 
of acute NIV were randomized to either standard medical 
treatment or standard medical treatment in combination with 
Home-NIV. Baseline PaCO
2
 was 59.3 mmHg (7.9 kPa) in 
the Home-NIV group (N=101) and 57.8 mmHg (7.7 kPa) 
in the control group (N=100). Follow-up after 1 year 
demonstrated that in this subgroup of COPD patients, 
no improvements in the time until readmission or death 
were achieved by supplementing the treatment strategy 
with Home-NIV.5 Nevertheless, Home-NIV was capable 
of improving day- and night-time hypercapnia, and there 
was a trend toward an improvement in HRQL.5 In contrast 
to this, a recently published multicenter study in the UK 
showed that the initiation of Home-NIV following an acute 
exacerbation of COPD requiring acute NIV therapy was 
associated with a substantially better outcome.6 In this study, 
patients were included if they presented with a PaCO
2
 level 
of .53 mmHg (7.1 kPa) after 2–4 weeks of resolution of 
respiratory acidosis in the period following acute-NIV.6 In a 
similar paradigm to that used in the Dutch study,5 patients 
(N=116) were randomized to receive either standard medical 
treatment that included LTOT (N=59) or standard medical 
treatment/LTOT in combination with Home-NIV. Each 
of the two groups showed a mean daytime PaCO
2
 level of 
59 mmHg (7.9 kPa). After a 12-month follow-up, patients 
who received Home-NIV in addition to LTOT experienced 
a longer time period until their next readmission or death 
(Home-NIV + LTOT: 4.3 months vs LTOT: 1.4).6 The main 
difference between the Dutch and the British studies was the 
time point at which the patient was recruited, and Home-NIV 
was initiated. Struik et al included patients after 48 hours of 
the acute event, whereas Murphy et al screened patients at a 
later time point, namely at around 2–4 weeks after resolution 
of respiratory acidosis.5,6 Patients from both studies showed a 
similar level of hypercapnia and respiratory failure type II at 
study initiation. Interestingly, however, Struik et al reported 
that a high number of patients in the standard treatment arm 
without Home-NIV (26%) become eucapnic within the first 
3 months of follow-up.5 This difference in the timing of 
patient selection might be an explanation for the different 
outcomes, since initiation of Home-NIV with persistent 
hypercapnia at least 2 weeks after acute exacerbation of 
COPD demonstrated a better outcome.6
In addition to the aforementioned criteria for prescrib-
ing Home-NIV, physicians involved in the provision of 
Home-NIV in Europe suggested that one of the most 
important indications for long-term NIV in COPD patients 
is the failure to wean from acute NIV.2 Although scientific 
evidence for this particular subgroup is lacking, it was noted 
in one of the abovementioned studies6 that 252 (12%) out of 
the 2,021 patients screened for the study eventually dropped 
out due to the inability to wean from in-hospital NIV. In line 
with these findings, Schönhofer et al analyzed data from the 
German WeanNet register to show that out of 6,899 patients 
who underwent prolonged weaning from mechanical ventila-
tion (registered between March 2008 and February 2014), 
19.4% started NIV during the weaning process due to 
persistent respiratory failure (type II).18 Within this patient 
cohort, the COPD subgroup showed marginal weaning 
success and thus represented the subgroup with the highest 
rate of NIV prescription.18 Furthermore, recently published 
German guidelines recommend Home-NIV therapy for 
COPD patients after prolonged weaning from mechanical 
ventilation if the patient’s symptoms of hypoventilation 
and hypercapnia can only be controlled with continuous 
use of NIV following weaning from invasive mechanical 
ventilation.10 This subgroup of COPD patients who fail to 
wean from acute NIV is a topic that urgently requires further 
clinical investigation, since it is practiced in many countries 
across Europe without any scientific basis.
Overall, it would be an interesting topic to investigate 
cost-effectiveness for the health care system regarding intro-
duction of NIV. However, there are currently no data avail-
able regarding this valuable topic and it would be difficult 
to compare this issue in regard to the divergence of health 
care systems and reimbursements from country to country. 
Nevertheless, in regard to the positive outcome in the afore-
mentioned British trial6 with a longer time period until their 
next hospital readmission in patients with COPD following 
establishment of NIV, one might speculate a positive effect 
on costs for the health care system. But this remains specula-
tive and needs further attention in future investigations.
ventilator settings and compliance
Besides the abovementioned issues of patient selection, 
adequate establishment of ventilator settings and targets for 
Home-NIV are thought to play a substantial role in treat-
ment success.1,19 Table 2 summarizes the ventilator settings, 
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most important Home-NIV trials on chronic hypercapnic 
COPD patients;5–8,11–13 this summary demonstrates that dif-
ferent approaches to ventilator settings have been used over 
the last two decades (Table 2). The increase in inspiratory 
positive airway pressures (IPAPs) is particularly apparent. 
This aspect is also addressed in Figure 1, where the IPAP 
levels used in short- and long-term trials are presented in 
graph form. In line with an Australian study,13 initial studies 
used moderate IPAP levels with a mean of 12–14 cm H
2
O 
and pressure support modes in combination with a nasal 
mask (Table 2).11–13 In all three of these trials, the chronic 
hypercapnic COPD patient subgroup was represented by a 
mean hypercapnia level of less than 55 mmHg (7.33 kPa) 
and showed no clear overall gain in benefit from Home-
NIV therapy, despite an acceptable level of tolerance to 
its daily use. By contrast, two more recent studies used a 
substantially different approach, with the higher IPAP levels 
of 22–24 cm H
2
O in combination with either a pressure-
controlled ventilation mode or a pressure-support mode 
with higher backup rates (Table 2).6,7 Each of these studies 
showed a significant improvement in outcome following the 
application of Home-NIV, as already discussed.6,7 Based 
on this observation, one could conclude that a substantial 
improvement in alveolar ventilation is needed both for 
Table 2 ventilator settings used in long-term randomized controlled trials on Home-NIv therapy for chronic hypercapnic COPD 
patients
Study (year) Patientsa Mean IPAP/EPAP Mode; mean backup 
rate
Interface Compliance
Casanova et al11 N=44 12/4 cm H2O Spontaneous mode; n/a Nasal mask 6.2 hours/day at 3 and 6 months; 
5.9 hours/day after 12 months
Clini et al12 N=86 14/2 cm H2O Spontaneous/timed mode; 
n/a
Nasal mask 9 hours/day
Mcevoy et al13 N=144 13/5 cm H2O n/a Nasal or full-face mask, according 
to patient comfort
n/a
Duiverman et al8 N=72 23/6 cm H2O Spontaneous/timed mode; 
18 breaths/min
Nasal, oronasal 6.9 hours/night at 24 months




Struik et al5 N=201 19/5 cm H2O Spontaneous/timed mode; 
15 breaths/min
Full-face mask (exception for 
1 patient with total face mask)
6.3 hours/night
Murphy et al6 N=116 24/4 cm H2O Spontaneous/timed mode; 
14 breaths/min
Nasal, oronasal, or total face mask, 
according to patient’s comfort
4.7 hours/night at 6 weeks; 
7.6 hours/night after 12 months
Notes: aNumber of patients randomized to either Home-NIv or standard treatment and follow-up.


































Figure 1 evaluation of IPAP levels used in Home-NIv for patients with chronic hypercapnic COPD.
Notes: Orange line indicates short-term trials;19–25 blue line indicates long-term trials.5–8,11–13,26,27
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treatment success and a better outcome in chronic hyper-
capnic COPD patients.1
Using Home-NIV with the aim of achieving normocap-
nia (“high-intensity NIV”) in chronic hypercapnic COPD 
patients was first proposed by Windisch et al in 2009.23 The 
same research group from Freiburg, Germany, then carried 
out a randomized cross-over short-term trial to demonstrate 
that this novel approach using high-intensity NIV was better 
tolerated by patients and was also superior in controlling 
nocturnal hypoventilation compared with conventional 
NIV, where IPAP levels of ~15 cm H
2
O were used.11–13,19 
It is also worth noting that there was a substantial differ-
ence in compliance (3.6 hours) in favor of high-intensity 
NIV.19 In line with this, Dreher et al showed in another 
study that sleep quality was not negatively influenced by 
high-intensity NIV when compared with the effects of a 
conventional NIV mode with lower IPAP levels.28 The 
results gained from these trials highlight the increasing 
trend toward the application of higher IPAP levels over 
the last two decades (Figure 1). Accordingly, Struik et al 
reported in their 2014 meta-analysis that higher IPAP levels, 
better compliance data, and higher baseline PaCO
2
 might 
contribute to improving PaCO
2
 outcome under Home-NIV 
therapy.3 This observation has been reinforced by positive 
results from more recent trials on the effects of NIV in 
COPD patients.3,6,7 Therefore, it has been proposed that 
improving elevated PaCO
2
 levels should form one of the 
main goals of Home-NIV.1,19
Regarding the application of increased IPAP levels, 
it should be noted that mechanical ventilation can affect 
cardiac output.15,29 An earlier physiological study reported 
that besides the positive effects of high-intensity NIV, it 
can also markedly reduce cardiac output, a factor that needs 
to be taken into consideration in patients with coexisting 
cardiac disease.30 On the other hand, the improvements 
conferred upon gas exchange by high-intensity NIV might 
be beneficial to the heart.15 This topic was addressed in a 
recent randomized-controlled feasibility study comparing 
the effects of high- vs low-intensity Home-NIV on cardiac 
output after 6 weeks of treatment.29 Here, cardiac output was 
assessed at baseline, at follow-up, and during NIV, as were 
gas exchange, lung function, and HRQL.29 The authors found 
no overall changes in patients (N=14) with respect to cardiac 
output or N-terminal pro b-type natriuretic peptide, although 
individual effects were observed, depending on the pressures 
applied or the coexistence of heart failure.29 Nevertheless, 
cardiac output can be reduced by the application of higher 
IPAP levels, especially in patients with preexisting heart 
failure and should therefore be applied with caution.29,30 
Despite this, there has so far been no reason for withholding 
Home-NIV therapy from chronic hypercapnic COPD patients 
due to concerns about adverse cardiac outcome.29
Next to IPAP levels, the mode of ventilation used 
in Home-NIV is an interesting aspect that has differed 
across countries over the last two decades.2,4 Nearly half 
the physicians who prescribed Home-NIV reported using 
techniques that were aimed at maximally reducing elevated 
PaCO
2
 levels, by the way of pressure-controlled or pressure- 
support ventilation modes with high inspiratory support 
of more than 20 cm H
2
O.2 The evolution of this treatment 
approach is in line with the aforementioned trend displayed 
in Figure 1 and Table 2. However, despite this trend, accord-
ing to the European survey by Crimi et al, pressure-support 
ventilation with low-intensity settings of less than 20 cm H
2
O 
remained the most-prescribed technique.2
Nowadays, volume-controlled ventilation only has a 
limited use in Home-NIV compared to its role 20 years 
ago.2,4 However, hybrid modes with target-volume settings 
on top of a pressure preset mode have become more popular 
over the last few years and have been the focus of several 
studies investigating the effects of Home-NIV on chronic 
hypercapnic COPD.31–35 All of these studies investigated 
patients with chronic hypercapnic COPD who were subjected 
to higher levels of IPAP, in line with the recommendation by 
Windisch et al.23 Three out of the four studies investigated 
patients who were already familiar with Home-NIV,31–33 
while the remaining study focused on the new hybrid mode 
in a Home-NIV-naive COPD subgroup.34 The randomized 
crossover trials investigating COPD patient subgroups who 
were already familiar with Home-NIV showed that adding 
target volume to pressure-preset NIV yielded neither benefits 
nor disadvantages with respect to sleep quality measured 
by polysomnography, HRQL, compliance, or gas exchange 
monitoring.31–33 However, patients who used target volume 
Home-NIV rated their own sleep quality at home as more rest-
ful compared to patients using the conventional NIV mode in 
one study.33 These results are corroborated by a randomized, 
parallel-group study of a COPD cohort naive to Home-NIV, 
where target-volume Home-NIV vs conventional NIV 
showed similar effects (eg, improvements in gas exchange 
monitoring, exercise capacity, compliance, pulmonary func-
tion, and HRQL).34 However, one advantage of target-volume 
NIV was that fewer titration days (secondary endpoint) 
were needed with this treatment approach (3.3±1.6 days) 
compared to the number required with conventional NIV 
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serve as a means for faster establishment of Home-NIV in 
chronic hypercapnic COPD patients, although this remains 
speculative and needs to be investigated further.
Selection of interface
In contrast to the topic of ventilator settings, the basis for 
selecting the appropriate ventilation interface has only so far 
received limited scientific attention.36,37 This is somewhat 
surprising because the type of interface has been reported 
to be crucial for the success of NIV therapy in the acute 
and chronic settings.38 In most of the studies discussed 
here, mask selection was based on patient comfort and/or 
the recommendation provided by the supervising ventila-
tion center (Table 2). There is a broad variety of interfaces 
available, including nasal masks, oronasal masks, total face 
masks, or mouth pieces, depending on patient needs and 
ventilation strategies.36 Nowadays, most of the interfaces are 
commercially manufactured, with the use of custom-made 
masks being less frequent. In addition, different types of 
masks are available with respect to the type of ventilator and 
circuit used for Home-NIV. Varieties of interfaces, including 
their advantages and disadvantages, are described in more 
detail elsewhere.36 The Eurovent Trial that was published 
20 years ago revealed that the predominant type of interface 
for patients using chronic ventilatory support was the nasal 
mask.4 This is in clear contrast to today, where prescribers 
in Europe reported using oronasal or full-face masks more 
often.2 In the Home-NIV studies outlined in Table 2 and 
Figure 1, a clear trend toward the more frequent use of 
masks that cover the nose and mouth can be seen. This 
development is likely attributable to the switch in ventilator 
settings (Table 2). Minor IPAP levels were generally applied 
at around the time of the Casanova et al, Clini et al, and 
McEvoy et al trials, and nasal masks served as the common 
interface, whereas later studies using higher IPAP levels were 
most likely to enlist the use of oronasal- or full-face masks 
(Table 2). As stated earlier, this decision was mainly trig-
gered by patient comfort and/or the recommendation of the 
supervising ventilation center. Although the scientific basis 
for interface selection is lacking, a recent single-center study 
in Germany investigated the distribution of interfaces among 
chronic hypercapnic COPD patients who were prescribed 
high-intensity Home-NIV.37 It was found that the majority 
(77%) of study patients (N=123) used a full-face mask, while 
only 23% used a nasal mask. Ventilator settings corresponded 
to those used in the Köhnlein et al study, which showed 
positive survival benefits in this particular subgroup.7,37 
Figure 2 represents the distribution of oronasal and nasal 
masks among different subgroups of COPD patients who 
received Home-NIV therapy.37 In particular, patients with the 
highest IPAP levels, a lower body mass index, or in whom 










































Figure 2 Distribution of oronasal (FFMs, dark gray) and nasal (NM, light gray) masks in different subgroups of COPD patients receiving Home-NIv therapy.
Notes: Blue horizontal line indicates the overall mean percentage of patients with FFM. Copyright© 2017. Dove Medical Press. Reproduced from Callegari J, Magnet FS, 
Taubner S, et al. Interfaces and ventilator settings for long-term noninvasive ventilation in COPD patients. Int J Chron Obstruct Pulmon Dis. 2017;12:1883–1889.37
Abbreviations: FFM, full-face mask; NM, nasal mask; Home-NIv, home mechanical noninvasive ventilation; BMI, body mass index; CRF, chronic respiratory failure; SAS, 
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their COPD were those with the highest degree of oronasal 
mask use.37 It is also important to note that there is a clear 
trend toward the increased use of masks covering the nose 
and mouth, as the practical application of IPAP levels rises 
(Table 2).2,37 However, further research is needed to elucidate 
the role of the interface in Home-NIV treatment of COPD 
and other subgroups of patients.
Conclusion
Home-NIV for patients with end-stage COPD has become a 
well-established form of therapy over the last few decades, 
despite a lack of consensus among the corresponding 
scientific literature. However, recent research trials have 
provided evidence that Home-NIV is associated with long-
term survival benefits as well as improvements in HRQL, 
gas exchange, and lung function. These positive results were 
first observed in the stable hypercapnic COPD patient sub-
group. Accordingly, a current study reported similar positive 
effects of Home-NIV therapy in this particular subgroup of 
COPD patients who suffer from an acute exacerbation that 
requires mechanical ventilation therapy and is accompanied 
by persistent hypercapnia – a generally severe event that is 
associated with a poor prognosis. Furthermore, there is a 
substantial number of patients who cannot be weaned from 
acute mechanical ventilation and hence qualify for Home-
NIV. However, this indication needs further attention, since 
scientific evidence is lacking. A treatment strategy with 
higher inspiratory pressures aimed at reducing elevated 
carbon dioxide levels appears to form the basis of therapeutic 
success, while a clear trend toward the use of oronasal masks 
is becoming apparent. New studies in this area are warranted 
to better understand the pathophysiological changes occur-
ring in patients using long-term ventilation. Focus should 
also be placed on selecting the most eligible candidates for 
Home-NIV, taking into account – but not solely focusing 
on – the degree of hypercapnia.
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